Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Chen, Huaqiua; b; c | Xie, Huanyub; c | Zhang, Yuanyuana; * | Wang, Guangminga; *
Affiliations: [a] School of Clinical Medicine, Dali University, Dali, Yunnan, China | [b] Xichang People’s Hospital, Xichang, Sichuan, China | [c] Affiliated Hospital of Xichang College, Xichang, Sichuan, China
Correspondence: [*] Corresponding authors: Yuanyuan Zhang, School of Clinical Medicine, Dali University, Dali 671000, Yunnan, China. Tel.: +86 0872 2201096; E-mail: [email protected]. Guangming Wang, School of Clinical Medicine, Dali University, Dali 671000, Yunnan, China. Tel.: +86 0872 2201096, E-mail: [email protected].
Abstract: BACKGROUND: Cervical cancer (CC) is a malignant tumor threatening women’s health. Replication factor C (RFC) 5 is significantly highly expressed in CC tissues, and the immune microenvironment plays a crucial role in tumor initiation, progression, and metastasis. OBJECTIVE: To determine the prognostic role of RFC5 in CC, analyze the immune genes significantly associated with RFC5, and establish a nomogram to evaluate the prognosis of patients with CC. METHODS: High RFC5 expression in patients with CC was analyzed and verified through TCGA GEO, TIMER2.0, and HPA databases. A risk score model was constructed using RFC5-related immune genes identified using R packages. Combining the risk score model and clinical information of patients with CC, a nomogram was constructed to evaluate the prognosis of patients with CC. RESULTS: Comprehensive analysis showed that the risk score was a prognostic factor for CC. The nomogram could predict the 3-year overall survival of patients with CC. CONCLUSIONS:RFC5 was validated as a biomarker for CC. The RFC5 related immune genes were used to establish a new prognostic model of CC.
Keywords: Cervical cancer, risk score, prognostic signature, immunoinhibitors, immunostimulators
DOI: 10.3233/CBM-220347
Journal: Cancer Biomarkers, vol. 37, no. 4, pp. 261-277, 2023
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]